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Abstract
Objectives. To describe the baseline characteristics of SLE patients requiring biologic therapy in the UK
and to explore short term efficacy and infection rates associated with rituximab (RTX) use.
Methods. Patients commencing biologic therapy for refractory SLE and who consented to join BILAG-BR
were analysed. Baseline characteristics, disease activity (BILAG 2004/SLEDAI-2K) and rates of infection
over follow-up were analysed. Response was defined as loss of all A and B BILAG scores to4 1 B score
with no new A/B scores in other organ systems at 6 months.
Results. Two hundred and seventy SLE patients commenced biologic therapy from September 2010 to
September 2015, most commonly RTX (n= 261). Two hundred and fifty (93%) patients were taking gluco-
corticoids at baseline at a median [interquartile range (IQR)] oral dose of 10 mg (520 mg) daily. Response
rates at 6 months were available for 68% of patients. The median (IQR) BILAG score was 15 (1023) at
baseline and 3 (212) at 6 months (P< 0.0001). The median (IQR) SLEDAI-2K reduced from 8 (512) to 4
(07) (P<0.001). Response was achieved in 49% of patients. There was also a reduction in glucocorticoid
use to a median (IQR) dose of 7.5 mg (512 mg) at 6 months (P< 0.001). Serious infections occurred in 26
(10%) patients, being more frequent in the first 3 months post-RTX therapy. A higher proportion of early
infections were non-respiratory (odds ratio = 1.98, 95% CI: 0.99, 3.9; P= 0.049).
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Conclusion. RTX is safe and is associated with improvement in disease activity in refractory SLE patients
with concomitant reductions in glucocorticoid use. Early vigilance for infection post-infusion is important to
further improve treatment risks and benefits.
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Rheumatology key messages
. Rituximab treatment is associated with improvement in disease activity in almost 50% of SLE patients.
. Infections occur most commonly in the first 3 months post-rituximab therapy in SLE patients.
. Access to biologic therapy is important to ensuring improved long term outcomes for SLE patients
Introduction
SLE is a complex autoimmune disease characterized by a
diverse range of clinical features. Patients are treated with
anti-malarial agents and glucocorticoids in conjunction with
immunosuppressive agents including AZA, MTX, MMF and
CYC, according to the extent of organ involvement [1].
Despite advances in therapy over the past 20 years, signifi-
cant numbers of SLE patients remain either refractory to
conventional immunosuppressive therapies or require un-
acceptably high glucocorticoid doses to control disease.
Biologic therapies have revolutionized the treatment of
many inflammatory conditions [2, 3]. B cells play a crucial
role in SLE pathogenesis and therapies that specifically
target B cells have shown the most promise to date.
Rituximab (RTX), a chimeric anti-CD20 mAb that transi-
ently depletes B cells, has been used for a number of
years with several case series, open-label trials and a
more recent meta-analysis reporting efficacy in refractory
SLE [47]. However two randomized placebo-controlled
trials (RCTs) of RTX in active SLE patients, Lupus
Nephritis Assessment With Rituximab Study (LUNAR)
and Exploratory Phase II/III SLE Evaluation of Rituximab
(EXPLORER), failed to reach their primary endpoints.
More recently the anti-BLyS antibody (belimumab),
which also targets B cells, has been licensed by the Food
and Drug Administration and European Medicines Agency
for the treatment of SLE based on two pivotal trials [8, 9].
Additional biologic agents such as tocilizumab and abata-
cept have failed to show efficacy for SLE in controlled trials
although post hoc trial analyses and case reports suggest
they may be useful in select patients [1012]. Thus the role
of biologic agents in the management of SLE remains to be
defined, with their long term safety and efficacy remaining
an ongoing area of debate.
Exploratory RCTs, by their nature, involve select patient
populations and focus on short term efficacy. Patients
with comorbid illnesses are frequently excluded and
therefore RCTs represent only a limited spectrum of pa-
tients. In clinical practice, treatment is likely to be pro-
longed and the patient population more heterogeneous.
Therefore, there is uncertainty as to whether the tolerance
and safety data obtained in RCTs can be extrapolated to
patients in routine practice.
Registry data are complementary to those of RCTs for
evaluation of safety and efficacy of biologic agents in real
world practice as exemplified by registry data on biologics
in RA [1318]. Registries capture information on patient
comorbidities and provide additional information on treat-
ment efficacy as they may analyse different populations
and the safety/efficacy of different treatment strategies
that have not been evaluated in RCTs. For example, pa-
tients with CNS involvement or severe LN have been
excluded from previous RCTs of biologics in SLE [8, 19].
Furthermore the use of prior immunosuppressive agents
such as CYC may exclude patients from clinical trials [20].
Thus registry data are reflective of the real-life condition of
patients requiring biologic therapy.
In response to the need to capture real world data on
the safety and efficacy of biologics in SLE, the BILAG es-
tablished the BILAG Biologics Register (BILAG-BR) in
2010. Modelled on the British Society of Rheumatology’s
RA Biologics Register, the primary aim of BILAG-BR is to
investigate whether biologic treatment in SLE is asso-
ciated with an increased rate of hospitalization for
infection compared with standard therapy. Secondary
end-points include treatment efficacy.
In this paper our primary objective was to describe the
baseline characteristics of patients commencing their first
biologic for refractory SLE in the UK who were enrolled in
BILAG-BR in the first 5 years of the register. We also
aimed to describe early efficacy of RTX over the first 6
months in the cohort as well as infections in the early
phase of follow-up post-RTX.
Methods
Inclusion criteria
Patients with SLE (1997 ACR or 2012 SLICC criteria [21,
22]) who were 55 years old, capable of providing in-
formed consent (parent/guardian for children) and had
commenced a new biologic therapy for treatment within
the last 12 months were included. Therapeutic decisions
are at the discretion of the treating rheumatologist and
since September 2013, in England has been informed by
the NHS England interim commissioning policy for the use
of RTX [23]. The commissioning criteria are as follows:
persistent active SLE (defined as at least one BILAG A
score and/or two B scores, or a SLEDAI-2K score >6)
and failure to respond or documented adverse events to
two or more standard immunosuppressive therapies
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(including one of MMF or CYC, unless contraindicated) in
combination with glucocorticoids. Failed response is
defined as being unable to achieve sustained disease
control and still having evidence of at least one BILAG A
or at least two BILAG B scores (or requiring unacceptably
high levels of long term oral glucocorticoids to maintain a
lower disease activity state).
We also enrolled a comparison cohort of patients with a
diagnosis of SLE,55 years old, who are within a month of
starting treatment with a non-biologic immunosuppressive
therapy (namely MMF, CYC, AZA or a calcineurin inhibitor).
Patient recruitment and baseline assessment
Patients were recruited by their treating clinician as part of
their scheduled care from 34 recruiting centres in the UK.
Patients consented to be flagged with the Health and
Social Care Information Centre for malignancies and
deaths. Disease activity (BILAG 2004 index [24] and
SLEDAI 2K [25]) and the SLICC Damage Index (SDI) [26]
were recorded pre-treatment and a baseline standardized
questionnaire was used to record demographic data
including age, gender and treatment group. Additional in-
formation was recorded including ACR/SLICC 2012 cri-
teria [21], organ involvement, disease duration, SLE
family history, presence of comorbidities, risk factors for
infections including vaccination history and current ser-
ology. Registration treatment (biologic/conventional im-
munosuppressant), the planned treatment schedule and
previous immunosuppressive/glucocorticoid treatment
(with reasons for discontinuation) were detailed as were
other current medications for lupus.
Patients were asked to provide blood and urine sam-
ples for future analysis at baseline pre-treatment as well
as at 3, 6 and 12 months post-biologic. The clinical data
were supplemented by a participant questionnaire regard-
ing quality of life and lifestyle factors.
Patient follow-up assessments
Patients were followed up at 3, 6 and 12 months for the
first year post-treatment and then annually for a minimum
of 2 years, with all recording occurring at the time of
scheduled clinic appointments. Patients requiring retreat-
ment or a switch in therapy (including from standard of
care to biologic) were followed for a minimum of 3 years
from the last change in treatment. Disease activity scores
were recorded at each review and the SDI was recorded
annually. Changes in biologic and standard lupus treat-
ment, glucocorticoid dose and concomitant medications
between visits were documented. New medical diagnoses
and adverse events were recorded, regardless of whether
causation was ascribed to treatment. We specifically
enquired as to the following adverse events of special
interest: infections, malignancy, hospitalization (for any
reason), pregnancy, operations (for any reason) and anti-
biotic courses (out-patient or in-patient).
Efficacy analysis
For the purpose of this analysis we adopted a response
definition informed by the NHS England interim policy for
RTX use [23] at 3 and 6 months using the BILAG-2004
Index as follows: improvement was defined as loss of all
A scores and loss of B scores to41 B score with no new
A/B scores in other organ systems. Persistent disease ac-
tivity was defined as an ongoing A score and/or52 B
scores with no new A/B scores in other organ systems.
Deterioration was defined as development of a new A
score in an organ system with baseline B or a new A or
B score in an organ system previously rated C/D/E.
The numeric BILAG-2004 global score was calculated
at each time point using the values: A = 12, B = 8, C = 1
and D/E = 0 [27].
Infection analysis
Infection-related events were coded using MedDRA software
(www.meddra.org). Serious infections (SIs) were defined as
any infection resulting in treatment with i.v. antibiotics, hos-
pitalization, disability or death. Infections occurring within 9
months of RTX use were deemed to be therapy-related, as
used in the BSR RA biologics registry [28].
Data analysis
Data were entered into a secure database at the
University of Manchester. Baseline demographic data
are presented using descriptive statistics performed
using Stata v13 (StataCorp, College Station, TX, USA).
The total number of responses available for each analysis
performed are shown throughout the text. Differences be-
tween groups was analysed using the non-parametric
MannWhitney test and results are presented as median
[interquartile range (IQR)]. Statistical significance was
defined as a P< 0.05 (two sided).
Ethics approval
Ethics approval was granted by the NRES Committee
North WestGreater Manchester West (REC: 09/H1014/
64) and the local Research and Development departments
at participant sites. All patients provided written informed
consent at the time of study registration.
Results
Baseline demographic data of patients commencing
biologic therapy
Between September 2010 and September 2015, 270 pa-
tients started biologic therapy for SLE. RTX was the com-
monest biologic agent prescribed (n= 261) followed by
belimumab (n= 7), abatacept (n= 1) and tocilizumab
(n= 1). Of these, 248 (92%) were female and the mean
(S.D.) disease duration was 8.4 (8.7) years (Table 1). One
hundred and twenty-four (60%) were Caucasian. The
most common ACR classification criteria recorded as
ever present up to and including the registration visit
were arthritis (233/266, 87%), ANA postive (231/266,
87%) and immunological involvement (176/266, 66%)
(Table 1). More patients were not working due to perman-
ent disability or were on sick leave due to their SLE than
were in permanent full time employment (29% vs 23%).
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Baseline disease activity
Two hundred and fifty (93%) completed BILAG-2004 and
247 (91%) SLEDAI-2K forms were analysed. With regard
to BILAG-2004, 164 A scores in 119 patients and 199 B
scores in 140 patients were recorded. Mucocutaneous
disease followed by musculoskeletal and renal involve-
ment were the systems most frequently recorded as
having a BILAG-2004 A score (Fig. 1A). Similarly mucocu-
taneous and musculoskeletal systems were the most fre-
quently scored ‘B’ items. Of note the renal and
neuropsychiatric systems were the only systems in
which a higher proportion of A scores were observed in
comparison with B scores (renal A : B = 29 : 2; neuro-
psychiatric A : B = 17 : 14).
The median (IQR) SLEDAI-2K score was 8 (512). The
systems distribution on the SLEDAI-2K is demonstrated in
Fig. 1B (complete data are available in supplementary
Table S1, available at Rheumatology Online). Serological
activity was the feature scored most often in patients with
59% (146/247) having either a low complement and/or
elevated dsDNA titre. Thirty per cent (73/247) had active
renal disease on the SLEDAI-2K at time of enrolment to
the register, the vast majority of which was attributable to
proteinuria (70/73). CNS activity was recorded in 18
patients.
Damage and co-morbidities
Baseline SDI scores were available in 233 (86%) patients,
the median (IQR) SDI score was 0 (01) and 41% (n= 96/
233) had one or more damage items. Damage was most
frequently observed in the musculoskeletal domain [n= 39
(17%); Fig. 2A] with deforming arthropathy [n= 17 (7%)]
and osteoporotic fracture [n= 12 (5%)] the most frequently
recorded items. Neuropsychiatric damage was recorded
in 29/233 (12%) patients.
TABLE 1 Baseline demographic and clinical characteris-
tics of SLE patients commencing biologic therapy in
BILAG-BR
Demographic characteristic
(no. of respondents) n (%)
Gender (n = 270)
Female 248 (92)
Male 22 (8)
Age, mean (S.D.), years 40.1 (14.6)
Duration from first criteria to
diagnosis, median (IQR), years
0 (02)
Disease duration, median
(IQR), years
6 (213)
Ethnicity (n = 208)
Caucasian 124 (60)
Asian 35 (17)
Caribbean 15 (7)
African 13 (6)
Mixed 12 (6)
Other 9 (4)
Family history of SLE (n = 256)
Yes 24 (9)
No 186 (73)
Do not know 46 (18)
Smoker (n = 210)
Current 32 (15)
Ever 82 (39)
Never 128 (61)
Education completed (n = 192)
Age 418 years 117 (61)
Employment (n = 211)
Disability/sick leave 62 (29)
Full-time employment 48 (23)
Part-time employment 42 (20)
Unemployed 9 (4)
Other (student/retired) 50 (24)
ACR criteria (n = 266)
Malar rash 148 (56)
Photosensitivity 146 (55)
Discoid rash 41 (15)
Mucosal ulcers 159 (59)
Arthritis 233 (87)
Serositis 90 (34)
CNS 29 (11)
Renal 111 (42)
Haematological 140 (53)
Immunological 176 (66)
ANA 231 (87)
FIG. 1 Baseline disease activity scores for SLE patients
upon entry into register
(A) Number of individual patients scoring either an A or B
on BILAG-2004 scoring system across the systems as-
sessed. (B) Number of individual patients scoring one or
more points across the systems assessed by SLEDAI-2K.
CNS includes seizure, psychosis, organic brain syndrome,
visual disturbance, cranial nerve disorder, lupus headache
and stroke. Renal includes proteinuria, haematuria, urinary
casts and pyuria. Serositis includes both pleurisy and
pericarditis. Serology included low complement and/or
elevated dsDNA either alone or in combination.
Cardioresp.: Cardiorespiratory; Con.: Constitutional; GI:
gastrointestinal; Haem.: haematological; Muc.: mucocu-
taneous; MSK: musculoskeletal; Neuro.:Neurological;
Ophthal.: Ophthalmic.
https://academic.oup.com/rheumatology 473
RTX use in refractory SLE
Two hundred (74%) patients had one or more other
comorbidities and the median (IQR) number of comorbid-
ities was 1 (02). Cardiovascular comorbidities (n= 77,
29%) were most common followed by depression
(n= 49, 18%) and chronic kidney disease (n= 33, 12%)
(Fig. 2B). Hypertension (n= 62, 23%) was the most fre-
quent cardiovascular co-morbidity. Baseline malignancy
history was confirmed with the UK Health and Social
Care Information Centre database; 19 cancers were
recorded in 18 (6.7%) patients. The commonest were cer-
vical (including CIN-III) (n= 7), lymphoma (n= 3) and non-
melanoma skin cancer (n= 3).
Baseline medication use
In total 243 (91%) patients were on antimalarial treatment.
HCQ was the most commonly prescribed antimalarial
(AM) amongst those patients on any AM (242/243, 99%).
Ten per cent of patients (28/268) had dual AM therapy.
Two hundred and fifty (93%) patients were receiving
glucocorticoid therapy (Table 2). The median (IQR) daily
oral prednisolone dose at baseline was 10 mg (7.520 mg).
Excluding i.v. methylprednisolone used as part of the RTX
pre-medication regime, additional parenteral glucocortic-
oids had been received by 127 (48%) patients. Of the
standard immunosuppressives used at baseline, MMF
was most frequently used (n= 183, 68%) (Table 2).
Efficacy of RTX
One hundred and seventy-eight RTX-treated patients had
complete baseline and 6-month assessments. Our pri-
mary definition of response (loss of all A and B BILAG
scores to41 B score with no new A/B scores in other
organ domains at 6 months) was achieved in 91 (51%)
and 88 (49%) patients at 3 and 6 months, respectively
(Fig. 3A). A further nine (5%) patients, eligible for RTX
due to requiring an unacceptably high dose of steroid to
maintain inactive disease, experienced no worsening in
disease control over the 6-month period post-RTX
treatment facilitating steroid reduction in these patients
[baseline prednisolone dose median (IQR) 10 mg
(9.2517.5 mg), 6-month dose 7.5 mg (510 mg)]. The
median (IQR) BILAG-2004 global score fell from 15
(1023) at baseline to 4 (213) at 3 months and 3 (212)
at 6 months (P< 0.0001). In total, 120 BILAG A scores
were recorded in 92 patients at baseline which fell to 30
and 34 A scores in 28 and 29 patients, respectively, at 3
and 6 months (P< 0.001). Similarly there was a significant
reduction in B scores over the 6-month follow-up [total
(no. of patients)]: baseline: 150 (n= 109); 3 months: 92
(n= 70); 6 months: 70 (n= 56) (P< 0.001).
One hundred and twenty-nine (72.5%) and 128 (71.9%)
patients had a reduction in SLEDAI-2K of> 1 point at the 3
and 6 months, respectively (Fig. 3B). The median (IQR)
SLEDAI-2K reduced from 8 (512) at baseline to 4 (28)
and 4 (07) at 3 and 6 months, respectively (P< 0.001).
Complete glucocorticoid dose data at each follow-up
time point were available for 149 patients. The median
(IQR) glucocorticoid dose across the cohort reduced
from 11.25 mg (8.37520 mg) prednisolone or equivalent
to 10 mg (6.815 mg) and 7.5 mg (512 mg) at 3 and 6
months post-RTX, respectively (P< 0.001 for both vs
baseline and 3 vs 6 months visit). One hundred and ten
FIG. 2 Rates of damage and comorbidity in SLE patients
requiring rituximab therapy
(A) Frequency of SLE patients scoring one or more points
across the individual domains assessed by SLICC-SDI.
(B) Frequency of comorbid conditions in SLE patients at
time of rituximab therapy. GI: gastrointestinal; MSK:
musculoskeletal; Pulm: pulmonary; PVD: peripheal vas-
cular disease.
TABLE 2 Prior/current medication use in refractory SLE
patients requiring biologic therapy
Medication type n (%)
Glucocorticoids (n = 268)
p.o. 233 (87)
i.v. 117 (44)
i.m. 10 (4)
Antimalarial (n = 268)
Any AM 243 (91)
HCQ 242 (90)
Dual AM therapy 28 (10)
Immunosuppressive agent (n = 268)
MMF 183 (68)
AZA 175 (65)
MTX 99 (37)
CYC
i.v. 65 (24)
p.o. 7 (3)
Ciclosporin 24 (9)
AM: antimalarial.
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(77%) patients were taking >7.5 mg of prednisolone at
baseline of whom 47 (43%) reduced to47.5 mg at 6
months.
A major clinical response, defined as BILAG-2004 C/D/
Es only with SLEDAI-2K 44 and daily oral glucocorticoid
dose47.5 mg, at 6 months was achieved in 33 (18.4%) of
patients. We also observed an increase in disease activity
post-RTX in 26 (15%) and 33 (19%) patients at 3 and 6
months, respectively. The mucocutaneous and renal sys-
tems were the most likely to have persistent disease ac-
tivity or manifest new organ involvement (Fig. 3C).
Infections following RTX exposure
One hundred and eighty-five infectious episodes were re-
ported in 82 (30%) patients during the 9-month period of
interest. Fifty-four (20%) patients suffered multiple infec-
tions. Twenty-nine (11%) SIs occurred in 26 patients. The
frequency of all infections and SIs is shown in Fig. 4A and
B. Respiratory (n= 88) and urinary tract infections (n= 36)
were the commonest infections observed. Within the first
3 months, 111 (60%) infections occurred while 60 (32%)
infections occurred between 3 and 6 months and 14 (8%)
between 6 and 9 months. A similar trend was noted for SIs
with 17 (59%) occurring within 3 months, 9 (31%) at 36
months and 3 (10%) at 69 months (Fig. 4C). The excess
infections observed in the first 3 months post-RTX were
related to a relative increase in non-respiratory infections
(respiratory vs non-respiratory infection: odds ratio = 1.98,
95% CI: 0.99, 3.9; P= 0.049).
Discussion
SLE remains refractory to conventional therapy for many
patients for whom biologic therapies offer the potential of
disease control and improved long term outcomes. Long
term real world data on patterns of use, response rates
and adverse events for such therapies is, however, lack-
ing. The BILAG-BR seeks to address these issues by
studying patients in a UK setting where the NHS and
expert groups have provided guidance for starting bio-
logic treatment.
Our data show that patients of non-Caucasian origin are
over-represented within the registry. Previous studies
from UK lupus centres show that 70% of the cohorts
are White Caucasian patients compared with 60% in the
BILAG-BR [29]. Given the equity of access to healthcare in
the UK we are likely to have included patients from less
advantaged populations who may have been excluded
from RCTs and cohort studies in different healthcare
environments. It is also recognized that there is a higher
incidence and prevalence of SLE in Asian and Afro-
Caribbean populations in the UK [30]. These ethnicities
experience more severe manifestations of disease such
as lupus nephritis and an overall poorer prognosis
[3133]. Thus in this setting of equal access to healthcare,
our register suggests that non-Caucasian patients are
more likely to have refractory disease that will require bio-
logic therapy.
The pattern of refractory disease is also of note. The
only organ systems with a higher proportion of BILAG A
scores than B scores were the neurological and renal do-
mains. Such severe organ involvement is routinely
excluded from non-lupus nephritis SLE trials [8, 9]. In add-
ition we observed a large proportion of patients with mod-
erate disease (represented by multiple BILAG B scores)
across two or more organ domains. Including such cases
of refractory disease across the whole disease spectrum
provides evidence that is not readily available from con-
ventional clinical trials. A significant number of BILAG-BR
patients commencing biologics already had co-morbid-
ities including renal impairment or history of malignancy
that again are usually exclusions in formal RCTs. The high
rates of baseline damage and glucocorticoid use confirm
these agents are being used in a population with a high
burden of disease sequelae where greater potential bene-
fits may be expected in long term follow-up. Baseline
damage and glucocorticoids have both been associated
with accumulation of further damage and mortality [29].
Taken together, such a real world sample of SLE patients
improves the generalizability of our findings to inform the
FIG. 3 Rates of response to rituximab therapy in refrac-
tory SLE
The percentage of patients (n = 178) with improvement,
persistent disease activity and deterioration in disease
activity following rituximab therapy at 3 and 6 months as
assessed by (A) BILAG 2004 Index vs baseline assess-
ment and (B) SLEDAI-2K. (C) The number of patients with
persistent disease or new organ involvement at 6-month
assessment as per BILAG organ domain. GI: gastro-
intestinal; MSK: musculoskeletal.
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management of severe refractory disease in routine
practice.
Previous case series as well as a detailed systematic
review have suggested efficacy of RTX in SLE [34], a result
not replicated in large RCTs [5, 19]. While the modest in-
clusion criteria in some case series may lead to an over-
estimation of the efficacy of RTX, design limitations with a
number of the clinical trials may in turn have led to an
underestimation of the effectiveness of the drug in refrac-
tory patients. Here we report that in a large cohort of
patients with refractory SLE, 50% of patients will experi-
ence early objective improvement in their disease in the
first 6 months following RTX. Although endpoints varied,
this rate is similar to the efficacy results observed in trials
of alternative biologic agents in SLE and substantially
greater than the 30% response in a RCT of RTX [19,
20, 9, 35]. This emphasizes that use of RTX is an important
treatment option for a large proportion of SLE patients
with refractory disease. Access to such biologic therapy
is vital to ensure optimal long term outcomes for patients,
by enabling better disease control while facilitating steroid
reduction. While improvement in disease activity indices
remained stable between the 3- and 6-month assess-
ments a further significant reduction in glucocorticoid
dose was observed between these two time points.
Given the role that glucocorticoids play in potentiating
damage in SLE, this observation supports previous case
series highlighting the potential benefits of glucocorticoid-
sparing regimes based on RTX in SLE [3638].
Furthermore these data will assist in informing expect-
ations with regard to expected efficacy of RTX (and
other biologics) in SLE and help to provide reliable out-
come estimates to power future SLE trials.
Future work identifying predictors of response to RTX is
ongoing. In this regard it is notable that almost one in five
patients achieved a major clinical response at 6 months.
In contrast, 19% of our cohort were noted to have a sig-
nificant deterioration in disease by this same time point.
While the extent and degree of peripheral B cell depletion
may be an important factor in predicting the response to
RTX, B cell depletion is associated with a corresponding
increase in BLyS levels that may play a role in propagating
disease [39]. Continued recruitment of patients as they
commence treatment will allow for a better understanding
of how we can predict treatment outcomes towards de-
veloping stratified medicine approaches for the use of
RTX (and other biologics) in SLE.
Regarding adverse events, no unexpected infection-
related events were observed. Seventy per cent of those
studied did not develop any infectious complications fol-
lowing RTX therapy with SIs observed in 10% of pa-
tients. These proportions are equivalent to those seen in
the studies of RTX in RA [40] as well as the EXPLORER
study (9.5%) [8], despite patients having greater rates of
co-morbidity and more severe organ involvement, in par-
ticular renal and CNS disease. The majority of infections
FIG. 4 Rituximab treatment is associated with an increased risk of infection
Rates of (A) all and (B) serious infections post-rituximab treatment in SLE patients. (C) The rate of all infections declined
over time with (D) the excess infection burden in the first 3 months being attributed to non-respiratory infections. GI:
gastrointestinal.
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(including severe infections) occurred in the first 3 months
post-RTX therapy, when patients were on the highest
doses of glucocorticoids, with a higher proportion of
these infections being non-respiratory in nature.
Therefore, pre-treatment strategies to reduce infection
such as vaccination, as well as extra vigilance for infection
in the 3-month window post starting RTX is required by
physicians and patients [4144]. The infection risk at this
time post-RTX may be explained by a number of factors
including the period of maximum B cell depletion, disease
activity itself, the effect of concomitant glucocorticoid and
cytotoxic use as well as potential RTX-associated hypo-
gammaglobulinaemia [45]. The timing of maximum impact
of these various factors will vary and warrants further
study. Ongoing recruitment of a control cohort of SLE pa-
tients starting conventional therapy will allow for future
analysis of patterns of infection in SLE and assist us in
identifying specific safety signals related to RTX.
Our study has a number of limitations inherent in any
registry. Firstly, complete data were not available for every
patient and the unblinded nature of any registry has the
potential to confound interpretation of results as does the
potential for inter-physician variability in assessing dis-
ease activity and reporting adverse events. Nonetheless,
given the large number of recruiting centres across the
UK, we feel that our results are both robust and general-
izable in the real-world setting. We have only reported
short term outcomes in this current study. However
longer term safety and efficacy data are being collected
as well as re-treatment use. The early changes in gluco-
corticoid doses will also be followed longer term to assess
if they are sustained.
In summary, SLE is refractory to conventional therapy in
a significant number of patients for whom biologic thera-
pies offer the potential of disease control and improved
outcomes. The BILAG-BR provides real-world data on
such patients recruited from multiple centres across the
UK. RTX use appears safe and efficacious in a subset of
SLE patients with 50% already having a good clinical re-
sponse at 6 months. Our results are comparable to the
response rates observed in other biologic trials in SLE. As
additional biologic agents become available for the treat-
ment of SLE, inclusion of these agents in the register will
allow for real-world comparison of their safety and effi-
cacy and may assist physicians in identifying patients in
their clinics who will benefit from the addition of a particu-
lar biologic therapy in an effort to improve their long term
outcome.
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